FDA Approves VALPROIC ACID — QUAGEN PHARMACEUTICALS LLC

# FDA Approves Quagen Pharmaceuticals' Generic Valproic Acid Oral Formulation Quagen Pharmaceuticals LLC received FDA approval for its generic valproic acid oral formulation (ANDA090517), enabling the company to compete in the established anticonvulsant and mood stabilizer market and potentially capturing market share from branded alternatives. The approval could increase competitive pricing pressure in the valproic acid segment while expanding treatment access for patients requiring this widely-used medication for epilepsy and bipolar disorder indications.